Clinical decision support alert fatigue is not solved by simply silencing more warnings. A safer, more effective 2026 approach requires teams to examine whether each alert is clinically meaningful, presented at the right moment, and supported by evidence that clinicians can readily trust. This practical case study follows a midsize health system that reduced override rates while preserving care speed by treating alert performance as a continuous quality and safety process rather than a one-time configuration cleanup.
The hidden cost of too many clinical alerts
When clinicians receive a steady stream of low-value warnings, they develop a predictable coping mechanism: they scan quickly, click through, and move on to the next task. In the short term, this keeps the visit moving. Over time, however, it creates a dangerous normalization of risk. A drug interaction that warrants immediate attention may be overlooked beside a routine reminder, a duplicate therapy notice, or an alert generated by incomplete data.
The health system in this case study operated a 420-bed hospital and a network of outpatient clinics using the same electronic health record. Its medicine teams reported that alerts appeared during prescribing, laboratory review, medication reconciliation, and discharge planning. Nurses received a different set of warnings, while ambulatory clinicians often encountered rules originally designed for inpatient workflows.
Rather than asking clinicians to “pay more attention,” the organization’s clinical informatics team proposed a structured clinical decision support systems audit. The goal was to measure the alert experience, identify the rules that offered little value, and redesign the system without creating a new class of unsafe silence.
Step one: establish a clinically governed audit
The first decision was to place the audit under joint clinical and technical governance. The project included physicians, nurses, pharmacists, quality leaders, patient safety staff, informatics specialists, and EHR analysts. Frontline participation was essential because alert burden is experienced differently across roles and settings.
The team began with four questions:
- Which alerts generate the highest override rates?
- Which alerts are linked to preventable harm, near misses, or high-risk medications?
- When do alerts interrupt work without improving the decision?
- Can the system distinguish a meaningful action from a technically correct but clinically irrelevant warning?
Instead of ranking alerts only by frequency, the team created a risk matrix. A common duplicate-therapy alert might generate thousands of overrides but present limited danger if therapy duplication is routinely intentional. Conversely, a rarely overridden alert for a serious interaction might warrant a high-priority review even if it fires infrequently.
The governance group also defined a protected category for “never disable without senior clinical review.” This included alerts related to allergies, dangerous drug-drug interactions, anticoagulation, pediatric dosing, and other situations where missed action could lead to severe harm.
Step two: measure the full alert lifecycle
The audit team reviewed 18 months of data, including alert fires, accept actions, overrides, override reasons, user role, care setting, medication involved, and time of day. They also examined whether clinicians changed their behavior after an alert appeared.
The analysis showed that the system’s overall override rate was 79 percent, but that number alone was misleading. Override rates varied substantially by rule:
- Some alerts were overridden because the medication combination was clinically appropriate.
- Some appeared after the order had already been placed, making interruption less useful.
- Some relied on outdated laboratory thresholds.
- Some were triggered by default data assumptions rather than the patient’s actual condition.
- Some lacked a clear reason for firing and prompted clinicians to select “other.”
One important discovery involved renal-function alerts. A single rule generated 6,000 alerts per month, and 92 percent were overridden. Clinicians explained that the alert often used a historical creatinine result even when a current result was available. In other cases, the message appeared while clinicians were still reconciling medications, before they had enough information to make a final decision.
The team did not treat these overrides as evidence of careless prescribing. They treated them as signals that the alert’s timing, data logic, and usability needed evaluation.
Step three: redesign alerts around decisions, not data availability
The most effective change was conceptual: alerts were redesigned around the clinician’s next decision rather than around the presence of a data point.
For example, an abnormal laboratory value should not automatically generate an interruptive warning if the value has already been reviewed, documented, and addressed. Similarly, an allergy alert may be appropriate during initial prescribing but unnecessary when renewing a longstanding medication with an accepted risk-benefit discussion.
The project team classified each rule into four groups:
- Actionable: The alert is supported by evidence, occurs before the decision, and requires a specific response.
- Refine: The clinical goal is useful, but the trigger, wording, timing, or data source should be improved.
- Retire: The alert addresses a low-value scenario, duplicates another warning, or is no longer consistent with current evidence.
- Protect: The alert addresses a high-risk situation and requires heightened review, even if overrides are common.
This classification prevented the audit from becoming a simple effort to maximize acceptance rates. A high override rate is not automatically a failure, and a low override rate does not guarantee that an alert improves care.
Step four: improve the interruptive threshold
Interventions were introduced gradually. For low-priority reminders, the system shifted from hard-stop alerts to passive indicators, dashboard tasks, or noninterruptive messages. The changes included:
- Delaying nonurgent medication alerts until the order was being finalized.
- Using current laboratory results instead of the most recent available value.
- Removing duplicate alerts that fired within the same workflow.
- Adding concise override reasons that reflected realistic clinical situations.
- Displaying the specific evidence behind a warning, such as the laboratory value, interaction severity, and guideline reference.
- Allowing appropriately trained clinicians to document an accepted exception without repeatedly re-entering the same information.
The team also introduced a “snooze” option for selected low-risk alerts. This gave clinicians a way to defer review until a later stage of the workflow without permanently ignoring the issue. Snoozing was monitored, and alerts were not eligible for suppression if they involved a time-sensitive or high-severity safety risk.
Step five: test changes without slowing care
Before deploying a revised rule, the team tested it against historical prescribing patterns. Analysts replayed patient scenarios to determine how many alerts the change would generate and whether any high-risk situations would be missed. Pharmacists reviewed the proposed logic, while frontline clinicians tested the wording and placement in simulation.
Changes were released in small groups and monitored for at least four weeks. The team tracked:
- Alert volume and override rate
- Time spent in the ordering workflow
- Number of medication safety events and near misses
- Use of each override reason
- Clinician feedback and help-desk tickets
- Differences between inpatient and outpatient settings
This approach made it possible to distinguish a genuinely improved alert from one that simply disappeared. If an alert volume fell but related safety events increased, the change was reconsidered. If clinicians spent less time on routine decisions without an increase in harm, the redesign was more likely to be successful.
What changed in the case study health system
Within six months, the health system reduced overall alert volume by 41 percent and the override rate from 79 percent to 63 percent. The number of alerts classified as nonactionable fell sharply, while the override rate for high-severity drug interaction alerts remained consistently low.
Several outcomes were especially important:
- Medication reconciliation alerts were moved closer to the point where clinicians needed to act.
- Renal alerts began using current laboratory results and patient-specific context.
- Duplicate alerts were consolidated into a single, clearer warning.
- Low-priority reminders became noninterruptive where appropriate.
- Pharmacists received a focused queue of genuinely high-risk cases.
Clinician feedback improved as well. Instead of describing the system as noisy, staff reported that alerts were more understandable and better timed. The project did not eliminate disagreement about every warning, but it created a process for resolving disagreement using evidence and data rather than anecdote alone.
A sustainable alert fatigue management program
The strongest result was not a single reduction in alert volume. It was the creation of an ongoing review process. New rules now require a clinical owner, an explicit purpose, expected actions, and a plan for monitoring effectiveness. Existing rules are reviewed at scheduled intervals and whenever relevant guidelines, medications, or workflows change.
The program also established quarterly “alert rounds” where clinicians can review recent overrides and safety events. These sessions do not punish individual prescribers. Their purpose is to identify whether the system is asking the right question at the right time.
For health systems beginning a similar initiative, the practical lesson is clear: reducing alert fatigue does not mean removing clinical decision support. It means making each alert earn the attention it requests. When alerts are clinically justified, accurately timed, transparent, and measurable, clinicians are more likely to trust them—and the system is more likely to improve patient safety without becoming an obstacle to care.
In conclusion, auditing clinical decision support requires more than tracking override percentages. The health system’s experience shows that safer alerts come from combining clinical governance, workflow analysis, data quality review, and continuous measurement. By replacing low-value interruptions with targeted, evidence-based guidance, the organization reduced burden while protecting the alerts that matter most.
